Anti-VEGF Antibodies Markets 2017-2022: Global Technology Assessment, Market Analysis and Future Growth Trends Report 2018 - ResearchAndMarkets.com

August 9, 2018

DUBLIN--(BUSINESS WIRE)--Aug 9, 2018--The “Anti-VEGF Antibodies: Global Technology Assessment, Market Analysis and Future Growth Trends” report has been added to ResearchAndMarkets.com’s offering.

Due to rapid advancements in genetic sequencing and the translation of basic medical sciences research into clinical practice, humanized mAbs have turnout to be fastest growing group of biotechnology-derived molecules in clinical trials. Driven by the growing application area pertaining to target disease viz. cancers, autoimmune disorders, infectious diseases, the monoclonal antibody market was valued over US$ 100 billion in 2017 and is forecast to grow at a double digit Compound Annual Growth Rate (CAGR) by year 2023.

Although various small molecule kinase inhibitors have been approved for targeting VEGF induced signaling, but the use of mAbs against VEGF have been established since FDA approval of Bevacizumab (Avastin, Genentech/Roche) in year 2004. Since, Avastin, FDA has approved ranibizumab (Lucentis, Genentech/Roche) and aflibercept (Eylea, Regeneron Pharma) both for cancer treatment and age related macular degradation (AMD). Therefore, use of mAbs in targeting VEGF induced angiogenesis in cancer, inflammation, arthritis and AMDs have tremendous potential in near future.

The report includes following key insights:

In this report we discuss the novel technologies/methodologies used for production, purification, structural modifications and formulation of mAbs against VEGF ligands in various human pathologies using technology distribution based on IP analysis The report highlights the significant trends in efficacy, limitations and patient survival rate anti-VEGF antibodies therapy based on data available for Avastin, Lucentis, Eylea, Vanucizumab, Brolucizumab and hPV19 This report showcases the competitive benchmarking of key industrial players like Roche, Sanofi, Novartis, Regeneron Pharma, AbbVie etc. in development of anti-VEGF antibodies from laboratory to clinical trials Product search and market forecast for trends in anti-VEGF mAbs will be extensively described The report will further include detailed description of anti-VEGF antibodies in clinical trials and their beneficial effects on targeted patients especially cancer and age related macular degradation, autoimmune diseases Report includes driving factors influencing global anti-VEGF mAbs market for year 2017-2022 Detailed description of SWOT and PEST analysis in development of anti-VEGF antibody therapy.

Key industry players

Roche Novartis Sanofi Regeneron Bayer AstraZeneca

Key Topics Covered:

1. Technology Overview

2. Anti-VEGF antibodies: Technology Segmentation

3. Anti-VEGF antibodies: Global IP Trends

4. Anti-VEGF antibodies: Different diseases targeted

5. Anti-VEGF antibody: White Space Analysis

6. Recent activities in development of anti-VEGF antibody

7. Anti-VEGF Antibody Technology Opinions from Experts

8. Anti-VEGF Antibody Technology Collaboration Insights

9. Strategies of Companies involved in development of Anti-VEGF antibody

10. Recent Anti-VEGF Antibody Product Developments

11. Global Trends Anti-VEGF Antibody Market

12. Global Anti-VEGF antibody development: Top Industrial Players

13. Anti-VEGF Antibody - Market Determinants

14. Anti-VEGF Antibody -Opportunity Vs. Restraints

15. Anti-VEGF Antibody: Strategic Analysis SWOT & PEST

16. Anti-VEGF Antibody Market Development (2017-2022)

17. Conclusion

Companies Mentioned

Roche Novartis Sanofi Regeneron Bayer AbbVie Zymeworks Elan Pharma Five Prime Therapeutics Kymab Ltd Pfizer AstraZeneca Boehringer Ingelheim

For more information about this report visit https://www.researchandmarkets.com/research/wkb849/antivegf?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180809005346/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Biotechnology,Immune Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/09/2018 07:26 AM/DISC: 08/09/2018 07:26 AM


Update hourly